{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "interpro:IPR003966",
      "entity_text" : "thrombin",
      "entity_type" : "family"
    },
    "hypothesis_information" : false,
    "context" : {
      "CellLine" : [ "cellosaurus:CVCL_F582" ],
      "TissueType" : [ "tissuelist:TS-0800" ],
      "Organ" : [ "uberon:UBERON:0010210" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "XREF_BIBR Previous in vitro study which measured thrombin generation at clinically relevant doses of sequence identical analogue of emicizumab in combination with aPCC and rFVIIa revealed significantly increased thrombin levels when SIA is combined with aPCC, suggesting that care should be taken when patients receiving emicizumab are treated with aPCC to control breakthrough bleedings.",
  "reading_complete" : "2020-08-03T14:41:47Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T14:40:22Z",
  "trigger" : "levels",
  "evidence" : [ "thrombin levels" ],
  "pmc_id" : "7373667",
  "score" : 0
}